Author:
Jafari Atefeh,Khalili Hossein,Dashti-Khavidaki Simin
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology,General Medicine
Reference117 articles.
1. US Food and Drug Administration: FDA report: background package for NDA 21-356: VIREAD (tenofovir disoxoproxil fumarate). 2001; Available from: http:// www.fda.gov/cder/approval/v.htm
2. Gitman MD, Hirschwerk D, Baskin CH, Singhal PC (2007) Tenofovir-induced kidney injury. Expert Opin Drug Saf 6(2):155–164
3. Jimenez-Nacher I, Garcia B, Barreiro P, Rodriguez-Novoa S, Morello J, Gonzalez-Lahoz J et al (2008) Trends in the prescription of antiretroviral drugs and impact on plasma HIV-RNA measurements. J Antimicrob Chemother 62(4):816–822
4. Hall AM, Hendry BM, Nitsch D, Connolly JO (2011) Tenofovir-associated kidney toxicity in HIV-infected patients: a review of the evidence. Am J Kidney Dis 57(5):773–780
5. Quinn KJ, Emerson CR, Dinsmore WW, Donnelly CM (2010) Incidence of proximal renal tubular dysfunction in patients on tenofovir disoproxil fumarate. Int J STD AIDS 21(2):150–151
Cited by
77 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献